Cargando…
Aminoglutethimide induced hormone suppression and response to therapy in advanced postmenopausal breast cancer.
Eighty-one postmenopausal women with advanced breast cancer were studied for the effects of treatment with aminoglutethimide (AG) plus hydrocortisone on peripheral hormones and response to therapy. There were 40 responders (R) and 41 non-responders (NR) at 3 months from the start of treatment. Plasm...
Autores principales: | , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1983
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2011499/ https://www.ncbi.nlm.nih.gov/pubmed/6684948 |
_version_ | 1782136541672374272 |
---|---|
author | Harris, A. L. Dowsett, M. Smith, I. E. Jeffcoate, S. |
author_facet | Harris, A. L. Dowsett, M. Smith, I. E. Jeffcoate, S. |
author_sort | Harris, A. L. |
collection | PubMed |
description | Eighty-one postmenopausal women with advanced breast cancer were studied for the effects of treatment with aminoglutethimide (AG) plus hydrocortisone on peripheral hormones and response to therapy. There were 40 responders (R) and 41 non-responders (NR) at 3 months from the start of treatment. Plasma oestrone concentrations were higher in non-responders at 1 and 2 months after starting AG (Means: NR 106 +/- 50, R 84 +/- 26 pmol l-1, P less than 0.05; highest value NR 121 +/- 51, R 99 +/- 24 pmol l-1, P less than 0.05). High oestrone levels were correlated with bulky liver secondaries, but not with age, tumour-free interval, time from last menstrual period, time from relapse to start of AG or body weight. Non-responders had higher mean prolactin levels on treatment (prolactin less than 500 mIUl-1 in 14/40 NR, 2/35 R, P less than 0.01). High oestrone or prolactin levels were present in 28/41 NR and 6/40 R (P less than 0.001). Dehydroepiandrosterone sulphate suppression did not differ between R and NR. The differences in peripheral endocrine environment in non-responding patients suggest that oestrogen metabolism may differ in non-responding patients and that sub-groups could be selected for rational endocrine therapy. |
format | Text |
id | pubmed-2011499 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1983 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-20114992009-09-10 Aminoglutethimide induced hormone suppression and response to therapy in advanced postmenopausal breast cancer. Harris, A. L. Dowsett, M. Smith, I. E. Jeffcoate, S. Br J Cancer Research Article Eighty-one postmenopausal women with advanced breast cancer were studied for the effects of treatment with aminoglutethimide (AG) plus hydrocortisone on peripheral hormones and response to therapy. There were 40 responders (R) and 41 non-responders (NR) at 3 months from the start of treatment. Plasma oestrone concentrations were higher in non-responders at 1 and 2 months after starting AG (Means: NR 106 +/- 50, R 84 +/- 26 pmol l-1, P less than 0.05; highest value NR 121 +/- 51, R 99 +/- 24 pmol l-1, P less than 0.05). High oestrone levels were correlated with bulky liver secondaries, but not with age, tumour-free interval, time from last menstrual period, time from relapse to start of AG or body weight. Non-responders had higher mean prolactin levels on treatment (prolactin less than 500 mIUl-1 in 14/40 NR, 2/35 R, P less than 0.01). High oestrone or prolactin levels were present in 28/41 NR and 6/40 R (P less than 0.001). Dehydroepiandrosterone sulphate suppression did not differ between R and NR. The differences in peripheral endocrine environment in non-responding patients suggest that oestrogen metabolism may differ in non-responding patients and that sub-groups could be selected for rational endocrine therapy. Nature Publishing Group 1983-10 /pmc/articles/PMC2011499/ /pubmed/6684948 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Article Harris, A. L. Dowsett, M. Smith, I. E. Jeffcoate, S. Aminoglutethimide induced hormone suppression and response to therapy in advanced postmenopausal breast cancer. |
title | Aminoglutethimide induced hormone suppression and response to therapy in advanced postmenopausal breast cancer. |
title_full | Aminoglutethimide induced hormone suppression and response to therapy in advanced postmenopausal breast cancer. |
title_fullStr | Aminoglutethimide induced hormone suppression and response to therapy in advanced postmenopausal breast cancer. |
title_full_unstemmed | Aminoglutethimide induced hormone suppression and response to therapy in advanced postmenopausal breast cancer. |
title_short | Aminoglutethimide induced hormone suppression and response to therapy in advanced postmenopausal breast cancer. |
title_sort | aminoglutethimide induced hormone suppression and response to therapy in advanced postmenopausal breast cancer. |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2011499/ https://www.ncbi.nlm.nih.gov/pubmed/6684948 |
work_keys_str_mv | AT harrisal aminoglutethimideinducedhormonesuppressionandresponsetotherapyinadvancedpostmenopausalbreastcancer AT dowsettm aminoglutethimideinducedhormonesuppressionandresponsetotherapyinadvancedpostmenopausalbreastcancer AT smithie aminoglutethimideinducedhormonesuppressionandresponsetotherapyinadvancedpostmenopausalbreastcancer AT jeffcoates aminoglutethimideinducedhormonesuppressionandresponsetotherapyinadvancedpostmenopausalbreastcancer |